These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 32945575

  • 21. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease.
    Ames MK, Atkins CE, Eriksson A, Hess AM.
    J Vet Cardiol; 2017 Jun; 19(3):218-227. PubMed ID: 28576479
    [Abstract] [Full Text] [Related]

  • 22. Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
    de Madron E, King JN, Strehlau G, White RV.
    Can Vet J; 2011 Nov; 52(11):1219-25. PubMed ID: 22547843
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.
    King JN, Hirakawa A, Sonobe J, Otaki H, Sakakibara N, Seewald W, Forster S.
    J Vet Sci; 2018 Jan 31; 19(1):117-128. PubMed ID: 28693297
    [Abstract] [Full Text] [Related]

  • 24. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
    Apple SM, Menciotti G, Braz-Ruivo L, Crosara S, Häggström J, Borgarelli M.
    Aust Vet J; 2016 Sep 31; 94(9):324-8. PubMed ID: 27569835
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease.
    Bernay F, Bland JM, Häggström J, Baduel L, Combes B, Lopez A, Kaltsatos V.
    J Vet Intern Med; 2010 Sep 31; 24(2):331-41. PubMed ID: 20102506
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
    Mizuno M, Yamano S, Chimura S, Hirakawa A, Takusagawa Y, Sawada T, Maetani S, Takahashi A, Mizuno T, Harada K, Shinoda A, Uchida S, Takeuchi J, Mizukoshi T, Endo M, Uechi M.
    J Vet Med Sci; 2017 Jan 20; 79(1):29-34. PubMed ID: 27644192
    [Abstract] [Full Text] [Related]

  • 27. Long-term Outcome of Irish Wolfhound Dogs with Preclinical Cardiomyopathy, Atrial Fibrillation, or Both Treated with Pimobendan, Benazepril Hydrochloride, or Methyldigoxin Monotherapy.
    Vollmar AC, Fox PR.
    J Vet Intern Med; 2016 Jan 20; 30(2):553-9. PubMed ID: 26936799
    [Abstract] [Full Text] [Related]

  • 28. Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.
    McManamey AK, DeFrancesco TC, Meurs KM, Papich MG.
    J Vet Intern Med; 2023 Jan 20; 37(6):2003-2010. PubMed ID: 37776546
    [Abstract] [Full Text] [Related]

  • 29. Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study.
    Schober KE, Rush JE, Luis Fuentes V, Glaus T, Summerfield NJ, Wright K, Lehmkuhl L, Wess G, Sayer MP, Loureiro J, MacGregor J, Mohren N.
    J Vet Intern Med; 2021 Mar 20; 35(2):789-800. PubMed ID: 33543810
    [Abstract] [Full Text] [Related]

  • 30. Database development and survival analysis in a clinical and historical cohort of dogs affected by myxomatous mitral valve disease treated or not with pimobendan using causal inference techniques.
    Bagardi M, Palermo V, Locatelli C, Colombo FM, Pazzagli L, Brambilla PG.
    Vet Res Commun; 2022 Jun 20; 46(2):481-486. PubMed ID: 35034282
    [Abstract] [Full Text] [Related]

  • 31. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ, Block CL, Laughlin DS, Oyama MA.
    J Vet Intern Med; 2018 Sep 20; 32(5):1509-1516. PubMed ID: 30216549
    [Abstract] [Full Text] [Related]

  • 32. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
    Rasmussen CE, Falk T, Zois NE, Moesgaard SG, Häggström J, Pedersen HD, Ablad B, Nilsen HY, Olsen LH.
    J Vet Intern Med; 2012 Sep 20; 26(1):76-84. PubMed ID: 22151356
    [Abstract] [Full Text] [Related]

  • 33. Pimobendan in heart failure therapy--a silver bullet?
    Gordon SG, Miller MW, Saunders AB.
    J Am Anim Hosp Assoc; 2006 Sep 20; 42(2):90-3. PubMed ID: 16527909
    [Abstract] [Full Text] [Related]

  • 34. Effect of torsemide and furosemide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease.
    Peddle GD, Singletary GE, Reynolds CA, Trafny DJ, Machen MC, Oyama MA.
    J Vet Cardiol; 2012 Mar 20; 14(1):253-9. PubMed ID: 22364690
    [Abstract] [Full Text] [Related]

  • 35. Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study.
    Boswood A, Gordon SG, Häggström J, Vanselow M, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Schummer C, Watson P.
    J Vet Intern Med; 2020 May 20; 34(3):1108-1118. PubMed ID: 32200574
    [Abstract] [Full Text] [Related]

  • 36. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
    Sarcinella F, Neves J, Maddox TW, Hodgkiss-Geere HM, Bode EF, Dukes-McEwan J.
    Open Vet J; 2020 Jan 20; 9(4):375-383. PubMed ID: 32042661
    [Abstract] [Full Text] [Related]

  • 37. The longitudinal outcome of canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: Baseline treatment characteristics.
    Franchini A, Borgarelli M, Abbott JA, Menciotti G, Crosara S, Häggström J, Lahmers S, Rosenthal S, Tyrrell W.
    J Vet Cardiol; 2022 Jun 20; 41():99-120. PubMed ID: 35316716
    [Abstract] [Full Text] [Related]

  • 38. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
    Borgarelli M, Ferasin L, Lamb K, Bussadori C, Chiavegato D, D'Agnolo G, Migliorini F, Poggi M, Santilli RA, Guillot E, Garelli-Paar C, Toschi Corneliani R, Farina F, Zani A, Dirven M, Smets P, Guglielmini C, Oliveira P, Di Marcello M, Porciello F, Crosara S, Ciaramella P, Piantedosi D, Smith S, Vannini S, Dall'Aglio E, Savarino P, Quintavalla C, Patteson M, Silva J, Locatelli C, Baron Toaldo M.
    J Vet Cardiol; 2020 Feb 20; 27():34-53. PubMed ID: 32032923
    [Abstract] [Full Text] [Related]

  • 39. Effect of sampling time on urinary electrolytes following oral furosemide administration in dogs with myxomatous mitral valve disease.
    Sabetti MC, Fidanzio F, Troìa R, Perissinotto L, Romito G, Mazzoldi C, Quintavalla C, Crosara S, Dondi F.
    J Vet Cardiol; 2022 Jun 20; 41():57-69. PubMed ID: 35245876
    [Abstract] [Full Text] [Related]

  • 40. Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study.
    Lefebvre HP, Ollivier E, Atkins CE, Combes B, Concordet D, Kaltsatos V, Baduel L.
    J Vet Intern Med; 2013 Jun 20; 27(5):1083-91. PubMed ID: 23869534
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.